KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Exchange Rate Effect (2019 - 2025)

Alnylam Pharmaceuticals' Exchange Rate Effect history spans 8 years, with the latest figure at -$5.7 million for Q4 2025.

  • For Q4 2025, Exchange Rate Effect rose 66.99% year-over-year to -$5.7 million; the TTM value through Dec 2025 reached $34.9 million, up 329.25%, while the annual FY2025 figure was $34.9 million, 329.25% up from the prior year.
  • Exchange Rate Effect reached -$5.7 million in Q4 2025 per ALNY's latest filing, down from -$927000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $27.5 million in Q2 2025 to a low of -$17.3 million in Q4 2024.
  • Average Exchange Rate Effect over 5 years is $482000.0, with a median of -$1.6 million recorded in 2022.
  • Peak YoY movement for Exchange Rate Effect: tumbled 2300.0% in 2024, then skyrocketed 981.6% in 2025.
  • A 5-year view of Exchange Rate Effect shows it stood at -$3.0 million in 2021, then skyrocketed by 153.08% to $1.6 million in 2022, then skyrocketed by 573.07% to $10.9 million in 2023, then tumbled by 258.49% to -$17.3 million in 2024, then soared by 66.99% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Exchange Rate Effect are -$5.7 million (Q4 2025), -$927000.0 (Q3 2025), and $27.5 million (Q2 2025).